NAD+

NCT05849519 · UNKNOWN

Small Sample，Unicentric，Randomized, Controlled Clinical Study of Coenzyme I for Injection in the Treatment of Sudden Sensorineural Hearing Loss

Sudden sensorineural hearing loss is one of the most common emergencies in otorhinolaryngology, and its incidence is increasing year by year and tends to be younger. At present, the pathogenesis of sudden deafness is not clear and the individual treatment effects vary significantly. In order to break through this specific treatment bottleneck, this project pioneered the clinical application of the co-regulator nicotinamide adenine dinucleotide (NAD+) in the treatment of sudden deafness. Therefore, this project intends to use pure tone audiometry, speech audiometry, tinnitus disability scale THI, tinnitus subjective visual analog score method VAS, ear fullness subjective visual analog score method VAS for data analysis, and explore the safety of coenzyme I for injection on sudden deafness and efficacy assessment.

Outcomes: Pure Tone Average(PTA) · Pure Tone Average(PTA) · Pure Tone Average(PTA) · Pure Tone Average(PTA) · Pure Tone Average(PTA) · Pure Tone Average(PTA) · Speech Recognition Rate · Speech Recognition Rate · Speech Recognition Rate · Speech Recognition Rate · Speech Recognition Rate · Speech Recognition Rate · Tinnitus Handicap Inventory · Tinnitus Handicap Inventory · Tinnitus Handicap Inventory · Tinnitus Handicap Inventory · Tinnitus Handicap Inventory · Tinnitus Handicap Inventory · Visual Analogue Scale of Tinnitus · Visual Analogue Scale of Tinnitus

NCT06505967 · UNKNOWN

Effectiveness of Qualia NAD+ Supplementation on Intracellular NAD Levels

The goal of this clinical trial is to determine if Qualia NAD+ effectively increases NAD+ levels in the blood and to evaluate its safety. Researchers will compare Qualia NAD+ to a placebo (a look-alike substance that contains no active drug) to assess its efficacy in increasing NAD+ levels in the blood. Participants will: Take Qualia NAD+ or a placebo every day for 4 weeks. Undergo blood tests before and after the trial.

Outcomes: NAD+ Levels in the Blood

NCT07692633 · NOT_YET_RECRUITING

A Clinical Trial to Assess the Absorption, Safety, and Efficacy of an Oral Nicotinamide Adenine Dinucleotide (NAD+) Supplement in Healthy Adults

The goal of this clinical trial is to assess the absorption, safety, and efficacy of an NAD+ supplement in healthy adults. The main question it aims to answer is: What is the change in NAD+ levels in whole blood from baseline to day 56 between the NAD+ supplement and placebo? Researchers will compare the NAD+ supplement to placebo to evaluate its absorption, safety, and efficacy. Participants will be asked to: * Complete questionnaires * Provide blood samples * Consume either the NAD+ supplement or a placebo for 55 days * Have their endothelial function evaluated

Outcomes: Change in NAD+ levels in whole blood from baseline to day 56 between the NAD+ supplement and placebo. · Change in NAD+ levels in whole blood from baseline to days 14 and 28 between the NAD+ supplement and placebo. · Change from baseline to days 28 and 56 between the NAD+ supplement and placebo in Cognitive function · Change from baseline to days 28 and 56 between the NAD+ supplement and placebo in appearance and aesthetics · Change from baseline to day 56 between the NAD+ supplement and placebo in energy and metabolism · Change from baseline to day 56 between the NAD+ supplement and placebo in cellular health and longevity · Change from baseline to day 56 between the NAD+ supplement and placebo in oxidative stress · Change from baseline to day 56 between the NAD+ supplement and placebo in cardiometabolic health

NCT04192136 · COMPLETED

NAD+ and Exercise in FA

Randomized, placebo-controlled trial with a 2x2 factorial design testing the effects of an NAD+ precursor (NR) and exercise on Peak VO2 and Si in Friedreich's Ataxia (FA). The primary objective of this research is to measure the effect of combination administration (NR + exercise) on aerobic capacity (Peak VO2) in FA. A key secondary objective is to measure the effect of combination administration (NR + exercise) on glucose homeostasis (Si) in FA.

Outcomes: Within-Participant Change in Peak V02 (Maximal Oxygen Uptake on Cardiopulmonary Exercise Testing) · Within-Participant Change in Whole Body Insulin Sensitivity (Si)

Results summary: {"participantFlowModule":{"preAssignmentDetails":"Once consent was obtained, participants were reviewed for eligibility and inclusion in the trial. Individuals meeting criteria were randomized. In total, 75 participants signed informed consent. There was 1 withdrawal of consent prior to in-person screening (ankle injury). 74 completed in-person screening. 8 were considered ineligible after screening due to: not reaching cadence during CPET (7) and not able to complete blood draw (1)","groups":[{"id":"FG000","title":"Nicotinamide Riboside (NR)","description":"Investigators will use Good Manufacturing Process (GMP)-grade 300 mg capsules of the dietary supplement nicotinamide riboside (ChromaDex, Irvine CA). Investigators dose based on body weight, and monitor for adverse effects (AEs).\n\nFor individuals with weight \\> 72 kg: 900 mg po qd x 12 wks.\n\nFor individuals with weight \\> 48 kg and ≤ 72 kg: 600 mg po qd x 12 wks.\n\nFor individuals with weight 24 ≤ 48 kg: 300 mg po qd x 12 wks.\n\nNicotinamide Riboside: Investigators will use (Good Manufacturing Process) GMP-grade 300 mg capsules of the dietary supplement nicotinamide riboside (ChromaDex, Irvine CA).\n\nNR is distributed by ChromaDex, Inc., Irvine, CA. NR is available as 300 mg capsules.\n\nThe dietary supplement will be re-labeled by the Hospital of the University of Pennsylvania (HUP) Investigational Drug Service according to FDA regulations, including subject and physician name and NR or Placebo 300 mg capsules."},{"id":"FG001","title":"Placebo","description":"Matched placebo will contain the same excipients without the active supplement and is generally recognized as safe. The placebo will be covered in an identical capsule (NR will be covered in the same capsule). Doses of placebo will match the body weight schema for dosing of NR. Investigators dose based on body weight, and monitor for adverse effects (AEs).\n\nFor individuals with weight \\> 72 kg: 900 mg po qd x 12 wks.\n\nFor individuals with weight \\> 48 kg and ≤ 72 kg: 600 mg po qd x 12 wks.\n\nFor individuals with weight 24 ≤ 48 kg: 300 mg po qd x 12 wks.\n\nPlacebo: The matched placebo will contain the same excipients without the active supplement and is generally recognized as safe. The placebo will be covered in an identical capsule (NR will be covered in the same capsule)."},{"id":"FG002","title":"Exercise Intervention and NR","description":"The exercise program consists of at-home training sessions: 3 aerobic sessions per week on the in-home bike trainer, and 2 resistance exercise sessions per week using resistance bands. All sessions will begin with stretching and brief aerobic warm-up exercise on the in-home bike trainer. On resistance days, subjects will be given instructions to complete circuits of resistance exercises.\n\nParticipants in this arm will receive both the Exercise Intervention and the NR.\n\nNicotinamide Riboside: Investigators will use (Good Manufacturing Process) GMP-grade 300 mg capsules of the dietary supplement nicotinamide riboside, distributed by ChromaDex, Inc., Irvine, CA.\n\nThe dietary supplement will be re-labeled by the Hospital of the University of Pennsylvania (HUP) Investigational Drug Service according to FDA regulations, including subject and physician name and NR or Placebo 300 mg capsules.\n\nExercise Intervention: On aerobic days, subjects will be given instruction on a recumbent Catrike trainer, titrated such that they spend 20 minutes at their target heart rate as determined by baseline Exercise Stress Test (EST) (60-80% of their heart rate at peak VO2) and as measured by their wearable device.\n\nOn resistance days, subjects will be instructed to complete circuits of resistance exercises. Training intensity (as determined by graded resistance bands) will be maintained at 60% of pre-training maximal voluntary contraction for each muscle group."},{"id":"FG003","title":"Exercise Intervention and Placebo","description":"The exercise program consists of at-home training sessions: 3 aerobic sessions per week on the in-home bike trainer, and 2 resistance exercise sessions per week using resistance bands. All sessions will begin with stretching and brief aerobic warm-up exercise on the in-home bike trainer. On resistance days, subjects will be given instructions to complete circuits of resistance exercises.\n\nParticipants in this arm will receive both the Exercise Intervention and the NR.\n\nNicotinamide Riboside: Investigators will use (Good Manufacturing Process) GMP-grade 300 mg capsules of the dietary supplement nicotinamide riboside, distributed by ChromaDex, Inc., Irvine, CA.\n\nThe dietary supplement will be re-labeled by the Hospital of the University of Pennsylvania (HUP) Investigational Drug Service according to FDA regulations, including subject and physician name and NR or Placebo 300 mg capsules.\n\nExercise Intervention: On aerobic days, subjects will be given instruction on a recumbent Catrike trainer, titrated such that they spe

NCT03707652 · COMPLETED

Open-label Study to Assess Increasing Levels of NAD+(Nicotinamide Adenine Dinucleotide)

The purpose of this study is to assess an effective single oral supplement or combination of oral supplements for increasing whole blood NAD+ levels.

Outcomes: Assess the mean change in NAD+ levels from baseline · Assess the mean change in AST (aspartate aminotransferase) levels from baseline · Assess the mean change in ALT (alanine aminotransferase) levels from baseline · Assess the mean change in Total Cholesterol levels from baseline · Assess the mean change in Triglycerides levels from baseline · Assess the mean change in LDL Cholesterol levels from baseline · Assess the mean change in HDL Cholesterol levels from baseline

NCT07563322 · RECRUITING

Mechanistic Study of Nicotinamide Riboside on NAD+ Biology in Individuals With Combined Pulmonary Hypertension

Pulmonary hypertension (PH) is a serious condition that puts strain on the heart and lungs and often leads to frequent hospital stays and shortened life expectancy. The most common cause is heart disease affecting the left side of the heart. A particularly high-risk form, called combined pre- and post-capillary pulmonary hypertension (CPH), occurs in about one in four people with heart failure. There are currently no approved treatments for CPH, and many patients develop right-sided heart failure and die earlier than expected. This study is based on a new approach that uses advanced computer methods to analyze a patient's unique biology and identify potential drug targets. Using this method, we identified nicotinamide riboside (NR) as a promising option for people with CPH. NR is a form of vitamin B3 that helps the body make NAD⁺, a substance essential for how cells produce energy and stay healthy. NAD⁺ plays an important role in how heart and blood vessel cells function. Previous research in animals suggests NR may help improve blood vessel changes in the lungs and support heart function. NR has also shown potential benefits in human studies related to cell energy, mitochondrial health, and reducing oxidative stress. In this study, NR is used only as a dietary supplement that supports normal body processes, not as a proven treatment. The investigators will conduct a small, carefully controlled study in which participants receive NR and a placebo at different times. The goal is to understand how NR affects biological and biochemical markers in the body, not to test whether it improves symptoms or outcomes. Any clinical measurements are included only to help interpret the biological effects.

Outcomes: Biochemical: Change in NADH:Ubiquinone Oxidoreductase Subunit B7 · Exploratory physiological measure: Change in 6-minute walk distance · Change in N-terminal pro-B-type natriuretic peptide Values · Change in New York Heart Association Functional classification (NYHA) · Change in Empahsis-10 score · Change in SF-36 Score · Change in Minnesota Living with Heart Failure Questionnaire · Change in Tricuspid annular plane systolic excursion · Change in RV Fractional Area · Change in RV Longitudinal Strain · Incidence of Treatment-Emergent Adverse Event · Number of patients with an incidence of death · Change in NAD+ · ,Change in NADH. · Change in Nicotinamide Mononucleotide